Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04339400
PHASE1

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

View on ClinicalTrials.gov

Summary

TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia cells which is caused by genetic abnormalities and viral infection.

Official title: A Single-group, Open-label, Multicenter, Phase I Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

79

Start Date

2018-11-20

Completion Date

2023-03-17

Last Updated

2026-06-03

Healthy Volunteers

No

Interventions

DRUG

TQ05105

TQ05105 is a JAK2 inhibitor.

Locations (2)

West China Hospital ,Sichuan University

Chengdu, Sichuan, China

Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China